Anavex Life Sciences Corp. (AVXL) Teams with Ariana Pharma to Advance Alzheimer’s and Parkinson’s Clinical Development Programs
Anavex Life Sciences (NASDAQ: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, this morning announced its collaboration with Ariana Pharma (Cambridge, MA and Paris, France) in which Anavex will use Ariana’s proprietary, FDA-tested KEM® (Knowledge, Extraction, Management) patient stratification technology to potentially accelerate ANAVEX 2-73’s ongoing phase 2/3 Alzheimer’s clinical development timelines. KEM® is a comprehensive clinical data analysis system that enables full exploitation of complex datasets including of smaller numbers of patients. To view the full press release, visit: http://nnw.fm/4D42d About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (NASDAQ: AVXL)…